Target- |
MechanismAngiogenesis stimulants [+2] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date16 Nov 2005 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date19 Oct 2005 |
|
MechanismTrypsin inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date16 Apr 1985 |
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study (TASK-UK)
The purpose of this study is to to compare the safety and effectiveness of IV urokinase with IV alteplase in the treatment of AIS in patients up to 6 hours from symptom onset.
A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China
A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients with Sepsis and Septic Shock in China
A Randomized, Blind, Placebo-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)
Compared with placebo, evaluate the effects and safety of Ulinastatin(UTI) added to conventional treatment for ARDS; Evaluate the dose response relationship of Ulinastatin for ARDS.
100 Clinical Results associated with Techpool Bio-Pharma Co., Ltd.
0 Patents (Medical) associated with Techpool Bio-Pharma Co., Ltd.
100 Deals associated with Techpool Bio-Pharma Co., Ltd.
100 Translational Medicine associated with Techpool Bio-Pharma Co., Ltd.